Merck’s Liptruzet Wins U.S. FDA Approval to Lower Cholesterol

Merck & Co. won U.S. marketing approval for Liptruzet, a combination of the company’s Zetia pill and a generic version of Pfizer Inc.’s Lipitor, to lower elevated levels of bad cholesterol.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.